# 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies

> **NCT00997945** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 15 (actual)

## Conditions studied

- Advanced Solid Malignancies

## Interventions

- **DRUG:** ZD4054 (Zibotentan)

## Key facts

- **NCT ID:** NCT00997945
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-09
- **Final completion:** 2011-04
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00997945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00997945, "10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00997945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*